

## Drugs and Pharmaceuticals Industry Highlights

### Contents

Chapter	Page	Chapter	Page
<b>Feature</b>	<b>1</b>	– Pharmexcil seeks export sops	
– Can India be Pharmaceutical Superpower in 2020?		<b>Regulatory News</b>	<b>12</b>
<b>News &amp; Views</b>		– Bulk drugs price fixation	
<b>Indian</b>		– Ceiling prices fixation	
<b>Industry News</b>	<b>8</b>	– Good laboratory practices amended: Effective from 1 <sup>st</sup> November 2010	
– Indian retail drug sales jump by 10%		– NPPA issues Guideline on Non-Scheduled formulation packs Re. Excise Duty Cut Guideline No. 5/2008 dated 10 December 2008	
– Small drug cos oppose MRP-based excise duty		<b>Global News</b>	<b>39</b>
– KAPL, RDPL now under government control		– Global generics sale declines	
– Sun raises offer by 23% for Taro’s residual stake		– European commission reveals pharmaceutical package	
– Taro rejects Sun Pharma’s revised buyout proposal		– European commission report claims generics entry blocked	
– Piramal purchases Minrad for \$40 million		<b>Healthcare News</b>	<b>42</b>
– Daiichi Sankyo to book losses on Ranbaxy acquisition		– WHO recommends global collaboration to tackle counterfeits	
– Apollo to foray into drug manufacturing			
– WHO may modify definition of fake drugs			

<b>Product News</b>	<b>44</b>	– Genzyme to collaborate with ICGEB	
– Ranbaxy-GSK to initiate phase-1 trial of respiratory drug		– Merck & Co. to enter generic biologics, invest in emerging markets	
– Glenmark may launch anti-diarrhoea drug by 2010		– Biotech firms take lead in clinical trial	
– Aurobindo Pharma gets approval in Canada for antifungal drug			
– ‘Rimonabant’ weight loss pill banned			
– Novo Nordisk to launch anti-diabetes drug in India by 2010			
– Roche to sell arthritis drug in India ahead of US			
– Cancer drug linked to blood clots			
– Sun Pharma gets USFDA nod for four generics			
<b>R&amp;D News</b>	<b>47</b>	<b>Patents</b>	<b>51</b>
– 96 <sup>th</sup> Indian Science Congress held		– Recent Indian patents in the field of drugs and pharmaceuticals	
– Science and Engineering Research Board to be set up		– Delhi High Court denies permission to market or manufacture drugs already patented	
– Mayuka Labs' research centre gets DSIR recognition		– Parliamentary panel against repeat clinical research for marketing generics	
– Global Pharma bodies to follow disclosure code for clinical trials		– Cipla challenges Delhi HC order on Nexavar	
– New technique for visualizing lung tumors		– DRL enters out of court settlement with Sepracor & Schering Corp	
– Hypocretin: key to nicotine addiction		– Nycomed files patent suit against Glenmark	
<b>Biotechnology</b>	<b>50</b>	<b>Parliament News</b>	
		<b>Lok Sabha</b>	<b>65</b>
		– Life saving drugs	
		– Sale of unapproved brand of medicines	
		– Vaccine for anthrax	
		<b>Rajya Sabha</b>	<b>67</b>
		– National pharma policy	
		– GMP for vaccine manufacturing PSUS	

---

***Views expressed in the journal are those of the authors and the Editorial Board/Publisher takes no responsibility for the same. We are a secondary abstracting service and the veracity of information is of the source quoted and not our primary responsibility.***

**Editor**